BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hampe CS, Yund BD, Orchard PJ, Lund TC, Wesley J, McIvor RS. Differences in MPS I and MPS II Disease Manifestations. Int J Mol Sci 2021;22:7888. [PMID: 34360653 DOI: 10.3390/ijms22157888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Leal AF, Benincore-Flórez E, Rintz E, Herreño-Pachón AM, Celik B, Ago Y, Alméciga-Díaz CJ, Tomatsu S. Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets. Int J Mol Sci 2022;24. [PMID: 36613919 DOI: 10.3390/ijms24010477] [Reference Citation Analysis]
2 Guffon N, Genevaz D, Lacombe D, Le Peillet Feuillet E, Bausson P, Noel E, Maillot F, Belmatoug N, Jaussaud R. Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study. Orphanet J Rare Dis 2022;17:448. [PMID: 36564803 DOI: 10.1186/s13023-022-02593-2] [Reference Citation Analysis]
3 Smith MC, Belur LR, Karlen AD, Erlanson O, Podetz-Pedersen KM, McKenzie J, Detellis J, Gagnidze K, Parsons G, Robinson N, Labarre S, Shah S, Furcich J, Lund TC, Tsai HC, McIvor RS, Bonner M. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of Ex Vivo Lentiviral Vector-Transduced Hematopoietic Stem and Progenitor Cells. Hum Gene Ther 2022;33:1279-92. [PMID: 36226412 DOI: 10.1089/hum.2022.141] [Reference Citation Analysis]
4 Minami K, Morimoto H, Morioka H, Imakiire A, Kinoshita M, Yamamoto R, Hirato T, Sonoda H. Pathogenic Roles of Heparan Sulfate and Its Use as a Biomarker in Mucopolysaccharidoses. IJMS 2022;23:11724. [DOI: 10.3390/ijms231911724] [Reference Citation Analysis]
5 Pierzynowska K, Żabińska M, Gaffke L, Cyske Z, Węgrzyn G. Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. European Journal of Cell Biology 2022;101:151232. [DOI: 10.1016/j.ejcb.2022.151232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Grant N, Sohn YB, Ellinwood NM, Okenfuss E, Mendelsohn BA, Lynch LE, Braunlin EA, Harmatz PR, Eisengart JB. Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair. Molecular Genetics and Metabolism Reports 2022;30:100845. [DOI: 10.1016/j.ymgmr.2022.100845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Sousa Martins R, Rocha S, Guimas A, Ribeiro R. Hunter Syndrome: The Phenotype of a Rare Storage Disease. Cureus. [DOI: 10.7759/cureus.21985] [Reference Citation Analysis]
8 Matsuhisa K, Imaizumi K. Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities for Mucopolysaccharidosis Type II. Int J Mol Sci 2021;22:12227. [PMID: 34830113 DOI: 10.3390/ijms222212227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]